The present invention relates to an improved process for preparation of Seratrodast of Formula I, which involves condensation of compound. of Formula I1 with compound of Formula I11 in presence of methanesulfonic acid.

The. present invention relates to a process for preparation of Loteprednol Etabonate of Formula-I which is highly pure and substantially free from the impurities of Formula-II, III and X. Formula-I Formula-Ill Formula-X Formula-II

The present invention describes anoral disintegrating film of Methylcobalamin. The film composition comprises an aqueous dispersion of Methylcobalamin and a film forming polymer and optionally one or more pharmaceutically acceptable excipients.

The present invention relates to a process for preparation of an intermediate of Formula III by purification involving simple process and use of said intermediate in the synthesis of the known pharmacologically active agent silodosin. The present invention further relates to the recovery of intermediate of Formul...

The present invention relates to an improved process for preparation of Ranolazine wherein the key intermediate i.e. N-(2, 6-dimethylphenyl)-l-piperazine acetamide is not isolated / purified and is in-situ reacted with 1 -Methoxy-2-(oxiranyImethoxy) benzene to obtain Ranolazine in high yield and purity. ...

The invention relates to a pharmaceutical composition comprising SGLT2 inhibitor or pharmaceutically acceptable salts, esters, solvates, polymorphs thereof and/or dipeptidyl peptidase-IV inhibitor or pharmaceutically acceptable salts, esters, solvates, polymorphs thereof optionally along with one or more pharmaceuti...

The present invention relates to an economic and industrially advantageous process for preparation of compound of Formula II in high yields and purity. Formula II The present invention further relates to the preparation of Anacetrapib by utilizing compound of Formula II as an intermediate.

The invention relates to a pharmaceutical composition comprising therapeutically effective amount of apremilast or pharmaceutically acceptable salts, ester, solvates, polymorphs thereof and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition is optionally coated with one or mor...

The present invention relates to the novel compounds of Formula I, and salts thereof and use of said compounds as intermediates for the preparation of (E)-2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxoprop-1-en-1-yl)phenoxy)-2-methylpropanoic acid (Elafibranor) of Formula II and its pharmaceutical acceptable salt...

The present invention relates to solid forms of elafibranor of Formula I, and process of preparation thereof, wherein said solid forms includes amorphous, crystalline, solid dispersion and premix with pharmaceutically acceptable polymer and/or carrier.

The present invention relates to a solid form of valsartan sacubitril trisodium complex and process of preparation thereof. The present invention further relates to an amorphous trisodium valsartan sacubitril complex and process of preparation thereof. The present invention further provides a pharmaceutical composi...

The present invention provides a substantially pure and a amorphous form of viloxazine, its isomers, or its pharmaceutically acceptable salts, process for the preparation and composition thereof. The present invention further relates to a solid dispersion and premix of viloxazine or pharmaceutically acceptable s...

The present invention provides a substantially pure and amorphous form of tozadenant or its pharmaceutically acceptable salts, process for the preparation and composition thereof. The present invention further relates to a solid dispersion of tozadenant and pharmaceutically acceptable salt thereof, comprising to...

The present invention relates to novel compounds of formula (I) as GPR119 agonist composition compositions containing such compounds and method of preparation thereof.

The present invention relates to novel crystalline forms of obeticholic acid of Formula I wherein said forms are stable and can easily be formulated. The present invention further relates to a process of preparation of crystalline forms of obeticholic acid wherein the process is reproducible. ...

The present invention relates to process for the preparation of a pyrrolidine compounds useful as key intermediate for the preparation of upadacitinib. More specifically the present invention relates to a process for preparing compound of Formula I, or pharmaceutically acceptable salts, polymorphs, isomers thereof. ...

The present invention relates to combinations of GPR119 receptor agonists with DPP-4 inhibitors and their use thereof for treating or preventing cardiovascular and metabolic disorders, including diabetes mellitus, non-alcoholic fatty liver disease (NAFLD), NAFL, NASH, dyslipidemia, and related disorders thereto. ...

There is provided a dosages form comprising silodosin and one or more pharmaceutically acceptable excipients. The present invention also provides a stable capsule dosages form comprising silodosin and one or more pharmaceutically acceptable excipients, wherein the dosages form is devoid of sugar alcohol. The inv...

The present invention relates to a process for preparation of nitrofurantoin monohydrate " and nitrofurantoin macrocrystals. The present invention further relates to the isolation of nitrofurantoin monohydrate and macrocrystals in pure form.

The  present  invention relates  to  novel  process  of preparation of various polymorphs/solid forms of apremilast. The present invention further relates to a new crystalline Form-MK of apremilast and the process of preparation thereof. The present invention further provides a composition comprising apremilast Form...

This present invention relates to pharmaceutical composition comprising empagliflozin wherein empagliflozin is in amorphous form. Further, this invention also relates to process for the preparation of said composition wherein empagliflozin is sprayed on an inert core which can be further formulated into a suitable p...

The present invention relates to novel compounds of Formula I and process of preparation thereof. Formula I wherein R is C1-C8 alkyl or, substituted or unsubstituted aryl, and M is an organic amine. The present invention further relates to use of said compounds as an intermediate for the preparation of angiote...

The present invention relates to a synthetic process for the preparation of chenodeoxycholic acid of Formula I, Remove Formula Formula I wherein compound of Formula I can be used for preparation of Obeticholic acid. The present invention further provides highly pure chenodexycholic acid comprising less than abou...

The present invention relates to a novel compound of Formula I and pharmaceutical acceptable salts thereof. Present invention further provides a process for the preparation of compound of Formula I and/or pharmaceutical acceptable salts thereof. Formula I Further, the present invention relates to a process of p...

The present invention relates to a process for the preparation of nitrofurantoin macrocrystal and a composition comprising said nitrofurantoin macrocrystal along with atleast one pharmaceutical acceptable excipients.

The present invention relates to novel compounds of Formula I and use of said compounds as intermediates for the preparation of Rosuvastatin and its pharmaceutical acceptable salts thereof. Formula-I wherein X is S or SO2.

The present invention relates to novel compounds of Formula-1 and process for preparation thereof that can be converted to serotonin 5-HT2A receptor antagonists and / or its pharmaceutical acceptable salts. The present invention further provides a novel process for the preparation of serotonin 5-HT2A receptor antago...

The present invention provides an industrially viable, cost effective process for manufacturing of sugammadex, its sodium salt and intermediate thereof. More particularly, the present invention further provides a purification methods of sugammadex and sodium salt thereof.

The present invention relates to the crystalline Forms A, B, C and D of fevipiprant of Formula I and preparation thereof. The present invention further provides amorphous solid dispersion of fevipiprant of Formula I with pharmaceutical acceptable excipients and process of preparation thereof FormulaI ...

The present invention relates "to a novel process for the preparation of lifitegrast of Formula I. The present invention further provides a novel process for the purification of lifitegrast of Formula I. Formula I.

The invention relates to an extended release oral pharmaceutical composition comprising a core, wherein the core comprises apremilast or pharmaceutically acceptable salts, ester, solvates, polymorphs thereof, at least one extended release polymer and one or more pharmaceutically acceptable excipients, wherein the co...

The present invention relates to the process of preparation of sacubitril and pharmaceutical acceptable salts thereof. Formula I The present invention further relates to the purification of sacubitril and its sodium salt and use of said sacubitril and/ or its pharmaceutical acceptable salt in preparation of valsart...

The present invention relates to a process for the preparation of doxepin hydrochloride of Formula-I. -o. The present invention further provides a crystalline form of doxepin hydrochloride and pharmaceutical composition comprising said crystalline form of doxepin hydrochloride along with at least one pharmaceut...

The present invention relates to a process for the preparation of 4-fluoro-a-[2-methyI-l-oxopropyl]-y-oxo-N-P-diphenylbenzenebutanamide, the diketone intermediate of atorvastatin of Formula I

The present invention relates to the novel compounds of Formula I, II and III and use of said compounds as intermediates for the preparation of compounds used for both SGLT1 and SGLT2 inhibition, such as Sotagliflozin.

The present invention relates to crystalline solvates of lifitegrast and process of preparation thereof. The present invention further relates to a composition comprising a crystalline solvate of lifitegrast along with at least one pharmaceutical acceptable excipients thereof. Dated this, 16th day...

The present invention relates to a process for preparation of sitagliptin phosphate. More particularly, the present invention relates to a process for the preparation of stable crystalline anhydrous form of sitagliptin phosphate.

The present invention relates to an improved process for the synthesis of propranolol hydrochloride of Formula I, which is used in the prevention and treatment of arrhythmia, angina pectoris, hypertension, myocardial infarction, coronary heart disease, hyperthyroidism etc.

The present invention relates to an improved process for the synthesis of succinylcholine chloride of Formula I or its~hydrate, which is a pharmaceutically active compound used as skeletal muscle relaxant. ju** V^Vca o Formula I

The present invention relates to a process for the preparation of succinylcholine chloride of Formula I and its hydrates, The present invention further provides a process for the purification of succinylcholine chloride of Formula I and specifically of succinylcholine chloride dihydrate of Formula II, ...

The present invention relates to the novel compounds of Formula I, II, III, IV and V, and use of said compounds as intermediates for the preparation of 4-({(1R)-2-[5-(2-fluoro-3¬ methoxyphenyl)-3-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-4-methyl-2,6-dioxo-3,6¬-dihydropyrimidin-1(2H)-yl]-1-phenylethyl}amino)butan...

The present invention relates to a novel solid form of lifitegrast of Formula I and process of preparation thereof. The present invention further provides a composition comprising said solid form of the lifitegrast along with atleast one pharmaceutical acceptable excipients.

The present invention relates to novel compounds of formula (I) process for preparation of the same and composition comprising these compounds.

The present invention relates to a process for preparation of etoricoxib of Formula I. . Further, the present invention provides an improved process for preparation of intermediate, ketosulfone and use in preparation of etoricoxib thereof.

The present invention relates to a process for the preparation of compound of Formula II and use of said compound in the preparation of 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl] methyl]pyrrolo[2,3-b]pyridine-3-yl]acetic acid [fevipiprant], Formula II wherein R is SO2Me or a leaving group. The pr...

The present invention relates to a novel process for the preparation of atorvastatin and its calcium salt of Formula I, . The present invention further relates to solid form of atorvastatin and its calcium salt wherein said solid form includes stable and substantially pure amorphous form of atorvastatin and its...

The present invention provides a solid dispersion of lasmiditan and salt thereof, comprising lasmiditan or its salts along with pharmaceutical acceptable excipients and process of preparation thereof. The present invention also provides a premix of lasmiditan comprising lasmiditan or its salt and at least one ph...

The invention relates to compounds of Formula II and Formula XII and process of preparation thereof, , and . The present invention further provides use of compounds selected from Formula II and XII in the preparation of piclidenoson. Moreover, present invention provides solid forms of picliden...

The present invention provides a process for preparation of lasmiditan & pharmaceutically acceptable salt thereof, by using compounds of Formula II, salts and polymorphs thereof, . Present invention also relates to a process for the preparation of compounds of Formula II, salts and polymorphs thereof. ...

The present invention relates to a novel process for the preparation of deutetrabenazine of Formula I and purification thereof. The present invention further relates to solid dispersion of deutetrabenazine with atleast one pharmaceutical acceptable excipient.

The present invention relates to a biocatalytic method for the preparation of ursodeoxycholic acid. The present invention further relates to chemical-biocatalytic method for preparation of chenodeoxycholic acid (CDCA) and use of said CDCA in preparation of ursodeoxycholic acid. ...

The present invention relates to novel compounds of Formula I and process of preparation thereof, Formula I The present invention further provides use of the compounds of Formula I in preparation Lumateperone of Formula II or pharmaceutically acceptable salts thereof, Formula II

Present invention relates to a process for preparation of lasmiditan & pharmaceutically acceptable salt thereof, by using novel intermediates of Formula II and X, salts and polymorphs thereof, , and Present invention also relates to a process for the preparation of novel intermediates of Formula II and X,...

The present invention provides lifitegrast substantially free from compound of Formula I, . Present invention further provides a process for the preparation of compound of Formula I for the identification and the quantification of itself in the lifitegrast.

The present invention provides a process for the preparation of lasmiditan of Formula I or pharmaceutically acceptable salt thereof, with high purity. . Present invention further provides a novel compound of Formula IV or its salt and use of said compound in preparation of lasmiditan and pharmaceutically ...

The present invention relates to a process of preparing a pharmaceutical composition of levalbuterol or its pharmaceutically acceptable salts and one or more pharmaceutically acceptable excipients in a suitable glass vessel, wherein said composition is having a long shelf life with reduced levels of impurities wh...

The present invention provides amorphous form of finerenone, its isomer, or its pharmaceutically acceptable salts, process for the preparation and composition thereof. The present invention further relates to a solid dispersion of finerenone, isomer, or pharmaceutically acceptable salt thereof, comprising fi...

The present invention provides a substantially pure and an amorphous form of azeliragon, or its pharmaceutically acceptable salts, process for the preparation and composition thereof. The present invention further relates to a solid dispersion of azeliragon, or pharmaceutically acceptable salt thereof, compr...

The present invention provides amorphous form of zuranolone or its pharmaceutically acceptable salts, process for the preparation and composition thereof. The present invention further relates to a solid dispersion of zuranolone or its pharmaceutically acceptable salts, comprising zuranolone or its pharmaceuti...

The present invention relates to compounds of Formula X or its salt and process of preparation thereof, . The present invention further relates to process for the preparation of Ozanimod of Formula I or its pharmaceutically acceptable salts, and compos...

The present invention provides a process of preparing amorphous form of apabetalone or pharmaceutically acceptable salts thereof. The present invention further relates to a solid dispersion of apabetalone and salt thereof, comprising apabetalone or its pharmaceutically acceptable salts along with pharmaceuti...

The present invention provides a substantially pure and a stable amorphous form of cenobamate or its pharmaceutically acceptable salts, process for the preparation and composition thereof. The present invention further relates to a solid dispersion of cenobamate and pharmaceutically acceptable salt thereof, ...

PREPARATION AND PURIFICATION PROCESS FOR SUGAMMADEX SODIUM ABSTRACT The present invention provides an industrially viable, cost effective process for manufacturing of sugammadex sodium and intermediate thereof. The present invention further provides a purification method of sugammadex sodium and intermediates ...

The present invention provides a substantially pure and a stable amorphous form of filgotinib or its pharmaceutically acceptable salts, process for the preparation and composition thereof. The present invention further relates to a solid dispersion and premix of filgotinib or pharmaceutically acceptable salt the...

The present invention provides amorphous form of balovaptan, or its pharmaceutically acceptable salts, process for the preparation and composition thereof. The present invention further relates to a solid dispersion of balovaptan, or salt thereof, comprising balovaptan, or its salts along with pharmaceutically ac...

The present invention relates to an improved process for the synthesis of propranolol hydrochloride of Formula I, The present invention further relates to a solid dispersion of propranolol and its hydrochloride salt with pharmaceutical acceptable excipients/ polymer.

The present invention relates to an improved and cost effective process for preparation of Ticagrelor in good yield and purity. The invention further relates to process for preparation of polymorphic Form-II of ticagrelor.The present invention further relates to a process for the preparation of amorphous solid dispe...

The present invention relates to a process for the preparation of amorphous trisodium valsartan: sacubitril, and composition thereof.

The present invention provides a pharmaceutical composition comprising bempedoic acid or pharmaceutically acceptable salt thereof and optionally one or more pharmaceutically acceptable excipient. The present invention further provides a process for preparing such compositions and their use thereof to treat cardiovas...

The present invention relates to an ophthalmic composition comprising olopatadine or pharmaceutically acceptable salts thereof and one or more pharmaceutical acceptable excipients. It further relates to a method of preparing such compositions and use to treat ocular allergic disorders (e.g. allergic conjunctivitis)....

There is provided a dosages form comprising rivaroxaban and one or more pharmaceutically acceptable excipients. The present invention also provides a stable capsule dosage form comprising rivaroxaban and one or more pharmaceutically acceptable excipients. The invention also relates to process of preparation of such ...

The present invention relates to a process for the preparation of revefenacin or pharmaceutically acceptable salt thereof. Present invention further relates to a pure and a stable solid forms of revefenacin or its salts, process for the preparation and composition thereof, wherein said solid form is selected fro...

The present invention relates to Dry Heat sterilization of Loteprednol Etabonate with sterilization monitoring indicators. The invention more particularly relates to Dry heat sterilization of Loteprednol Etabonate API for Ophthalmic Suspension and gel preparation. The indicators used in this invention enable routi...

The present invention relates to a stable pharmaceutical composition comprising vasopressin or pharmaceutically acceptable salts thereof. The present invention further provides a method of increasing blood pressure in adults with vasodilatory shock by administering said pharmaceutical composition of vasopressin or p...

The present invention provides an amorphous form of voxelotor or its pharmaceutically acceptable salts, process for the preparation and composition thereof. The present invention further relates to a solid dispersion of voxelotor or pharmaceutically acceptable salt thereof, comprising voxelotor or its salts alon...

The present invention relates to an ophthalmic composition comprising brinzolamide or pharmaceutically acceptable salts thereof, and brimonidine or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. It further relates to a method of preparing such compositions and the...

The present invention relates to novel compound of Formula III, isomers or pharmaceutically acceptable salts thereof, and use of said compounds as intermediates in the preparation of cenobamate of Formula I or pharmaceutically acceptable salt thereof. The present invention further provides substantially pur...

The present invention relates to an ophthalmic composition comprising bimatoprost or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients. It further relates to a method of preparing such compositions and their use for the reduction of elevated intraocular pressure in pati...

The present invention relates to compounds of Formula A, isomers, polymorphs and process of preparation thereof, wherein, S is a pharmaceutically acceptable salt, R is selected from hydrogen or C1-C3 alkyl group substituted with R4; wherein R4 is selected from -CN, -COR5; wherein R5 is selected from NR6R7, -OR8; whe...

The present invention relates to a novel process of preparation of pimavanserin of Formula I and pharmaceutical acceptable salts thereof. Formula I The present invention further relates to substantially pure amorphous form of pimavanserin tartrate and process of preparation thereof. The present invention furtherm...

The present invention relates to substantially pure solid forms of valsartan disodium and process of preparation thereof. Specifically the present invention relates to amorphous and crystalline form of valsartan disodium. The present invention further provides stable solid form of valsartan disodium having moist...

The present invention relates to a pharmaceutical composition comprising obeticholic acid and one or more pharmaceutical acceptable excipients.

The present invention provide solid forms of lanifibranor or pharmaceutically acceptable salt thereof, wherein said solid form is selected from amorphous form, crystalline hydrates, solvates; and process of preparation thereof. The present invention further relates to a solid dispersion of lanifibranor and ph...

The present invention provides a process of preparing amorphous form of evenamide or pharmaceutically acceptable salts thereof. The present invention further relates to a solid dispersion of evenamide and salt thereof, comprising evenamide or its pharmaceutically acceptable salts along with pharmaceutically ...

This present invention relates to pharmaceutical composition comprising fixed dose combination of valsartan or pharmaceutically acceptable salts thereof and sacubitril or pharmaceutically acceptable salts thereof. Further this invention also relates to process for the preparation of said composition and use of the s...

The present invention relates to a novel compound of Formula IV and use of said compound for the preparation of 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl] methyl]pyrrolo[2,3-b]pyridine-3-yl]acetic acid [fevipiprant], Formula IV wherein A is SO2Me, halogen or a leaving group. The present invention fu...

NOVEL COMPOUNDS AND THEIR USE IN PREPARATION OF OBETICHOLIC ACID OR PHARMACEUTICAL ACCEPTABLE SALTS THEROF The present invention relates to the novel compounds of Formula I, and use of said compounds as intermediates for the preparation of 6-(alpha-ethylchenodeoxycholic acid), or (3a, 5(3, 6a, 7a)-6-ethyl-3,7-dih...

The present invention provides a stable pharmaceutical composition comprising lifitegrast and one or more pharmaceutical excipients, wherein the pharmaceutical composition is free of antioxidant and/or preservative. It further relates to a method of preparing such compositions, filling into suitable single-dose or m...

The present invention relates to an improved process for the preparation of Rosuvastatin calcium. The present invention further relates to a crystalline forms A and B of a compound of Formula II which are used as intermediate for the preparation of Rosuvastatin calcium.

A container packaging assembly system comprising of a plurality of components of an aluminium body structure comprising of a container stand (1), a rotary motor (2), a cam-follower system (3), a nozzle inserter (4), a cap tightening system (5), a container clamping or mounting part (6), a torque measurement dev...

NOVEL COMPOUNDS AND USE IN PREPARATION OF OMECAMTIV MECARBIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF ABSTRACT Present invention relates to novel compounds of Formula A, its pharmaceutically acceptable salts, and polymorphs thereof. Present invention further relates to process of preparing compounds o...

The present invention provides pharmaceutical composition comprising bempedoic acid and one or more lipid lowering drug. The present invention further provides method of preparing such composition and its use for treating or reducing the risk of cardiovascular diseases.

A PROCESS FOR THE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYLPIPERIDINE-4-CARBONYL)PYRIDINE-2-YL]BENZAMIDE AND SALTS THEREOF ABSTRACT The present invention provides a process for preparation of 2,4,6-trifluoro-n-[6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl]benzamide (lasmiditan) and pharmaceutically accep...

Present invention provides a process for the preparation of sacubitril of Formula I, pharmaceutical acceptable salts, and solid forms thereof, Formula I . The present invention further provides stable amorphous form of sacubitril or its pharmaceut...

The present invention relates to an improved and cost effective process for preparation of ticagrelor in high yield and purity. The present invention further relates to a process of purification of ticagrelor. Dated this, 11th Day of Feb., 2021 For Mankind Pharma Ltd. ...

The present invention relates to a pharmaceutical composition comprising revefenacin or its pharmaceutically acceptable salts and one or more pharmaceutically acceptable excipients. It further relates to a process for making such composition and its use for treatment of chronic obstructive pulmonary disease (COP...

Present invention relates to novel compounds of Formula II, its pharmaceutically acceptable salts, and polymorphs thereof. Formula II Present invention further relates to process of preparing compounds of Formula II and use in preparation of Omecamtiv Mecarbil and its pharmaceutically acceptable salts. ...

The present invention relates to solid forms of methyl-4-[[2-fluoro-3-[(6-methylpyridin-3-yl)carbamoyl amino] phenyl] methyl] piperazine-1-carboxylate of Formula I or pharmaceutically acceptable salts, solvates or hydrates thereof, methods for preparation and pharmaceutical compositions thereof. ...

Present invention relates to improved process for the preparation of Upadacitinib by involving use of pure intermediates. Particularly, the present invention relates to process for the preparation of substantially pure intermediates and use in the preparation of Upadacitinib thereof.

STABLE PHARMACEUTICAL COMPOSITION OF ETELCALCETIDE ABSTRACT The present invention relates to a stable pharmaceutical composition comprising etelcalcetide or a pharmaceutically-acceptable salt thereof. The present invention further provides a method of treating hypercalcemia or hyperparathyroidism by administerin...

The present invention relates to process of preparing ISATX247 or its pharmaceutically acceptable salt and process of purification thereof. The present invention further relates to various solid forms of ISATX247 or their pharmaceutically acceptable salt. It further relates to the pharmaceutical composition compris...

The invention relates to an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer, optionally one or more pharmaceutically acceptable excipients.

The present invention relates to solid forms of Omecamtiv Mecarbil (methyl 4-[(2-fluoro-3-{[N-(6-methylpyridin-3-yl) carbamoyl]amino}phenyl) methyl] piperazine -1-carboxylate) of Formula I or salts thereof, and methods for preparation thereof.

The present invention relates to a process for the preparation clozapine of Formula I or salts, hydrates thereof, NH CI Formula I The present invention further provides a process for the purification of clozapine of Formula I or salts, hydrates thereof.

An object of the invention is to provide compounds as selective JAK1 inhibitor, a process for preparation of the inhibitors, a composition containing the compounds and utility of the compounds.

The present invention relates to inhibitors of apoptosis signal-regulating kinase 1 ("ASK1"), a process for synthesis of the compounds of the present invention, composition comprising the compounds and use of the compounds for inhibition of ASK1.

The present invention relates to a pharmaceutical composition comprising Varenicline or its pharmaceutically acceptable salt with reduced amount of nitrosamine impurity and a process for preparing the same.

The present invention relates to a stable pharmaceutical composition of a therapeutically active agent, with reduced amount of nitrosamine impurities and a process for preparing the same. Dr. Anil Kumar Chief Scientific Officer

The present invention relates to pharmaceutical combinations of peroxisome proliferator-activated receptor (PPAR) agonist(s) with sterol absorption inhibitor(s), as well as to the use of these combinations for treating and/or preventing non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (...

The invention relates to an extended release oral pharmaceutical composition comprising upadacitinib or its pharmaceutically acceptable salts thereof, a hydrophobic release controlling agent and optionally one or more pharmaceutically acceptable excipients. The present invention further relates to a process for ...

ABSTRACT PROCESS FOR THE PREPARATION OF REMOGLIFLOZIN, IT’S INTERMEDIATES, ETABONATE SALT AND PURIFICATION THEREOF The present invention provides a process for the preparation of Remogliflozin etabonate and intermediates thereof. The present invention further relates to process of purification of Remoglifl...

ABSTRACT The present invention relates to a packaging laminate and process for preparation thereof, wherein said packaging laminate is easy to tear, has excellent barrier properties, and mechanically strong enough for convenient handling. Dated this, 9th day of September, 2022 For Mankind Pharma Ltd....

ABSTRACT The present invention relates to a stable ophthalmic composition comprising loteprednol or its pharmaceutically acceptable salt thereof, one or more suspending agents, and optionally one or more excipients. Dated this the 13th day of May 2022. For Mankind Pharma Ltd. ...

NOVEL PROCESS FOR THE PREPARATION OF CISATRACURIUM OR ITS SALT THEREOF ABSTRACT The present invention relates to process of preparation of Cisatracurim or its salt of Formula IIa by involving use of novel compound of Formula I . where X- is an anion selected from chloride, bromide, iodide, tetrafluor...

PROCESS FOR THE PREPARATION OF HALOPERIDOL, ITS INTERMEDIATES, SALT AND PURIFICATION THEREOF ABSTRACT Present invention provides a process for the preparation of Haloperidol of Formula I, its intermediates, salt and purification thereof, Formula I Present invention further pr...

The present invention relates to liquid dispensing container made of material comprising a matrix in which antimicrobial beads are dispersed and evenly distributed throughout the container, wherein said beads have an antimicrobial effect and wherein said containers are configured to store preservative free thera...

ABSTRACT The present invention relates to a topical pharmaceutical composition comprising dydrogesterone, and one or more pharmaceutically acceptable excipients. Moreover, the present invention also relates to the process for the preparation of the topical pharmaceutical composition. Dated this the 12th...

ABSTRACT Present invention provides novel process of preparing Netarsudil and pharmaceutically acceptable salts thereof and more specifically the present invention further provides compound of Formula II or pharmaceutically acceptable salts thereof, which act as intermediates for the preparation of Netarsudil a...

A PARENTERAL PHARMACEUTICAL COMPOSITION OF DYDROGESTERONE ABSTRACT The present invention relates to a parenteral pharmaceutical composition comprising therapeutically effective amount of dydrogesterone, and one or more pharmaceutically acceptable excipients. Further, the present invention also relates to the p...

The present invention relates to a stable ready-to-use parenteral composition comprising therapeutically effective amount of phenylephrine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. Dated this the 10th day of May 2024. ...

The present invention relates to stable and bioavailable pharmaceutical formulations useful for the oral administration comprising Semaglutide and one or more permeation enhancers, and process for their preparation. Oral administration of the formulations of the present invention can be used for the treatment of...

The present invention provides a synergistic pharmaceutical combination comprising a topical composition comprising Euphorbia Prostrata and an oral composition comprising Euphorbia Prostrata, wherein said topical and oral compositions comprises one or more pharmaceutical acceptable excipients and optionally one...

ABSTRACT The present invention provides a pharmaceutical combination comprising a Euphorbia Prostrata and Ispaghula husk. The combination and compositions of present invention are suitable for the treatment of piles, haemorrhoids, haemorrhoids during pregnancy, anal fissures, and/or anal fistula. Dated ...

ABSTRACT The present invention provides a topical composition of Euphorbia Prostrata, optionally comprising one or more pharmaceutically active agent, wherein said composition is suitable for the treatment of haemorrhoids, haemorrhoids during pregnancy, anal fissures, anal fistula, and varicose veins. ...

Present invention provides improved process for the preparation of Sitagliptin or its pharmaceutically acceptable salt. Present invention relates to a process for the preparation of Sitagliptin Phosphate using novel intermediate of Formula II.

PHARMACEUTICAL COMPOSITION COMPRISING PURE EXTRACT OF EUPHORBIA PROSTRATA ABSTRACT The present invention provides a pharmaceutical composition comprising pure extract of Euphorbia Prostrata substantially free of heavy metals and microbial contamination, wherein said extract has a controlled particle size and t...

The Present invention provides novel compound of Formula II or pharmaceutically acceptable salts thereof, which act as intermediates for the preparation of Abrocitinib and pharmaceutically acceptable salts thereof. Formula II The Present invention further provides process for the preparation novel compoun...

IMMEDIATE RELEASE PHARMACEUTICAL COMPOSITIONS OF DYDROGESTERONE AND A KIT THEREOF ABSTRACT The present invention relates to an immediate release pharmaceutical composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof, along with one or more pharmaceutically acceptable excipients. ...

The present invention relates to an improved process for the preparation of Rocuronium Bromide. The invention further relates to an improved process for the preparation of Rocuronium Bromide free of residual solvents; diacetyl impurity; des-pyrrolidine keto impurity as well as other impurities, ...

ABSTRACT The present invention relates to an improved process for preparation of Rosuvastatin or its pharmaceutical acceptable salt. The present invention further provides an improved process for the preparation of Rosuvastatin calcium by using compound of Formula I and III. ...

ABSTRACT Present invention provides process for the preparation of Latanoprostene Bunod using compound of Formula III or V. Formula III, wherein P is H or amine protecting group and X is a halogen. Dated 10th Day of Mar, 2023 For Mankind Pharma Ltd. ...

ABSTRACT Present invention provides process for the preparation of Latanoprostene Bunod and intermediate thereof. Present invention further provides process of purification of Latanoprostene Bunod and intermediate thereof. Dated 26th Day of Feb, 2024 For Mankind Pharma Ltd. ...

A STABLE OPHTHALMIC COMPOSITION OF PHENYLEPHRINE ABSTRACT The present invention relates to a stable ophthalmic composition comprising therapeutically effective amount of phenylephrine or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients. The present invention furt...

PHARMACEUTICAL COMPOSITION OF LIFITEGRAST ABSTRACT The present invention provides a stable pharmaceutical composition comprising lifitegrast and one or more pharmaceutical excipients, wherein the pharmaceutical composition is free of antioxidant and/or preservative. It further relates to a method of preparing such...

ABSTRACT The invention relates to a stable pharmaceutical composition comprising levothyroxine or a pharmaceutically acceptable salt thereof, along with one or more pharmaceutically acceptable excipients. The present invention further provides a stable pharmaceutical composition comprising about 325 mcg to abou...

The present invention relates to an ophthalmic composition comprising netarsudil or pharmaceutically acceptable salts thereof; bimatoprost or pharmaceutically acceptable salts thereof and one or more pharmaceutical acceptable excipients. It further relates to a method of preparing such compositions and use t...

The Present invention provides stable amorphous form, solid dispersion of Fezolinetant of Formula I and their process of preparation. Present invention further provides novel crystalline forms of Fezolinetant and their process of preparation. Dated 14th Day of August, 2024 For Mankind Pha...

The present invention provides an amorphous form of Resmetirom, method for its preparation. This invention also provides amorphous solid dispersion and premix of Resmetirom. The present invention also provides pharmaceutical compositions containing the same. Dated 28th Day of August, 2024 For Ma...

The present invention relates to a parenteral pharmaceutical composition comprising a therapeutically effective amount of Dydrogesterone or its pharmaceutically acceptable salt, and one or more pharmaceutically acceptable excipients. The present invention further provides a parenteral pharmaceutical composit...

The present invention relates to the pharmaceutical composition comprising dydrogesterone or ester (s) thereof in combination with aromatase inhibitor or salts thereof and one or more pharmaceutically acceptable excipients for the treatment or prevention of uterine disorders preferably uterine fibroids, aden...

Present invention provides novel process for the preparation of Abrocitinib compound of Formula I or its pharmaceutically acceptable salts thereof. Present invention provides novel compound of Formula II or pharmaceutically acceptable salts thereof, which act as intermediates for the preparation of Abroc...

The present invention relates to a pharmaceutical combination comprises of dydrogesterone or its ester (s), anthelmintic agent, wherein the said pharmaceutical combination is used for the treatment of uterine disorders preferably uterine fibroids, adenomyosis, endometriosis, heavy menstrual bleeding, or pain...

Present invention provides novel salts of Mavacamten compound of Formula I, Present invention further provides process for the preparation of novel salts of Mavacamten compound of Formula I. Dated 11th Day of Sept, 2024 For Mankind Pharma Ltd. ...

The present invention relates to a vaginal tablet for insertion into vagina comprising dydrogesterone or pharmaceutically acceptable salts or esters thereof, along with one or more pharmaceutically acceptable excipients. Dated this, 25th Day of September, 2024 ...

The present invention relates to a pharmaceutical combination comprises of Tyrosine kinase inhibitor, and HMG-CoA reductase inhibitor or antiprotozoal drug for the treatment of cancer. Further, the present invention also relates to a pharmaceutical composition comprising Tyrosine kinase inhibitor, HMG-CoA re...

The present invention relates to a composition comprising anthelmintic drug and antifungal agent along with one or more pharmaceutically acceptable excipients, where in the composition used for the treatment of cardiovascular diseases such as heart attack (myocardial infarction) or heart failure. Additiona...

Present invention provides novel intermediates or pharmaceutically acceptable salts thereof which are used for the preparation of Fezolinetant of formula I. Dated 03rd Day of Oct, 2024 For Mankind Pharma Ltd. ...

The present invention relates to amorphous and crystalline Forms of Phenytoin sodium specifically Forms MK-1, MK-2, and MK-3 of Phenytoin sodium of Formula I. The present invention further provides the process of preparation of the amorphous and crystalline Forms MK-1, MK-2, and MK-3 of Phenytoin sodium. ...

The purpose of the present invention is to provide an economical, industrially efficient, and convenient process for the production of Perfluorohexyloctane of Formula I with high yield and is suitable for large-scale production. The present invention also provides a process for the purification of Perfluorohe...

The present invention provides a suppository composition comprising Euphorbia Prostrata, one or more pharmaceutically acceptable excipients, wherein said composition is suitable for the treatment of haemorrhoids, haemorrhoids during pregnancy, anal fissures, anal fistula, and varicose veins. Further, the pre...